Last checked at 8 Aug 2017 16:23
8 August 2017
IXICO plc
("IXICO" or the "Company")
Share option grant
IXICO plc (AIM: IXI) ('IXICO' or the 'Company'), the digital technologies company serving neuroscience, announces a grant of options over the ordinary shares in the Company in accordance with the rules of the Company's EMI Share Option Plan 2014 (the 'Plan') exercisable at a price of 34p (being the closing middle market price per ordinary share on 7 August 2017).
The award of options under the Plan is subject to certain performance conditions and the options granted will vest upon the achievement of strategic corporate goals in respect of commercialisation of the Company's products and/or services or a significant corporate development transaction occurring within three years of the date of grant.
The total number of options being issued at this time is 713,940 and includes a grant of options to Susan Lowther, Chief Financial Officer of the Company, as follows:
Name of Director | Number of options granted | Total number of options held | Percentage of issued share capital under option |
Susan Lowther | 235,000 | 545,196 | 2.01% |
For further information please contact:
IXICO plc Giulio Cerroni, Chief Executive Officer Susan Lowther, Chief Financial Officer and Company Secretary
|
Tel: +44 20 3763 7499 |
Shore Capital (Nomad and Broker) Bidhi Bhoma / Edward Mansfield /James Wolfe | Tel: +44 20 7408 4090 |
FTI Consulting Limited (Investor Relations) Simon Conway/Mo Noonan | Tel: +44 20 3727 1000 |
About IXICO
IXICO is the digital technologies company serving neuroscience. Our mission is to transform the pursuit of improving brain health through the application of digital technologies to neuroscience. IXICO's specialist data analytics services are used by the global pharmaceutical industry to select participants for clinical trials, assess the safety and efficacy of new drugs in development and in post marketing surveillance. Our neurological disease focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis, Parkinson's disease and our integrated digital platform encompasses the entire drug development lifecycle. It is a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable sponsors to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new companion digital health products targeted at improving patient outcomes.
More information is available on www.IXICO.com